. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Expo Health. 2020 May 21;13(1):51–64. doi: 10.1007/s12403-020-00361-w

Table 4,

Odds ratios for elevated anxiety and depression symptoms and AChE inhibition.

	OR (95% CI)
	Depression	Anxiety
Categories of AChE inhibition
−34% to −12.5% (n=60)	7.84 (1.84, 33.4)	0.80 (0.36, 1.76)
−12.4% to −6.5% (n=61)	2.35 (0.57, 9.81)	1.00 (0.43, 2.32)
−6.4% to <0.0% (n=60)	3.37 (1.00, 11.43)	0.64 (0.24, 1.70)
0.0% to 70.3% (n=119)	Ref.	Ref.
	OR per 10% inhibition in AChE activity (95% CI)
	Depression	Anxiety
All	1.67 (1.04, 2.66)	0.97 (0.75, 1.25)
Age (tertiles)^a
11.0–13.4y (n=99)	0.70 (0.24, 2.09)	1.22 (0.65, 2.27)
13.5–15.2y (n=97)	2.09 (0.31, 14.11)	3.01 (0.93, 9.78)
15.3–17.9y (n=105)	3.74 (1.29, 10.88)	0.87 (0.49, 1.56)
Gender
Female (n=153)	2.72 (1.23, 6.00)	0.99 (0.73, 1.34)
Male (n=147)	1.18 (0.59, 2.37)	0.93 (0.59, 1.47)

Adjustments: age, gender, AChE activity in April, hemoglobin concentration (baseline and follow-up), z-score for height-for-age, z-score for BMI-for-age, and family income.

Not adjusted for age